Chief Executive Officer
Antimicrobial Resistance (AMR) has become one of the world’s greatest threats to public health, with over 1,27 million deaths worldwide today, and an estimated 10 million deaths a year by 2050. Because of AMR, infections are increasingly difficult to treat, and the resulting medical needs are high.
It is estimated that 63.5% of cases of antibiotic-resistant bacterial infections are healthcare-associated. Acute respiratory infections associated with healthcare (HAP/VAP) continue to be a frequent complication of hospital care, accounting for 22% of all nosocomial infections. These respiratory infections are the most common source of infections leading to sepsis, accounting for 47% of cases.
We focus all our efforts on identifying and developing innovative products with the ability to address clear unmet medical needs associated to bacterial infections and increasing AMR, in acute hospital settings, aligned with viable clinical development plans based on a precision medicine concept.
"We are thrilled to welcome Dr Manos Perros as our new Chairman of the Board and Dr Marco Taglietti as…
Commenting on the appointment, AUROBAC THERAPEUTICS CEO Florence Séjourné: “I am delighted that Martin is joining us. His incredibly strong…